Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35440506/
2022 Apr 19;194(15):E556-E560. doi: 10.1503/cmaj.211478. 1 Centre for Health Services and Policy Research (McClean, Law) and Centre for Health Evaluation & Outcome Sciences (Bansback), School of Population and Public Health,...
Relevance: We evaluated the current state of biosimilar policies and use across Canada, highlighting 3 illustrative cases — insulin glargine, infliximab and etanercept. We briefly discuss interchangeability and indication extrapolation before making suggestions for enhancing the market through harmonization of biosimilar policies, patient and...
Patient and Caregivers' Perspectives on Biosimilar Use in Pediatric Inflammatory Bowel Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35442227/
The majority of pediatric patients and caregivers had never heard of biosimilars. Caregivers that had heard of biosimilars prior to the study were more likely to have a negative perception...
Conclusion: The majority of pediatric patients and caregivers had never heard of biosimilars. Caregivers that had heard of biosimilars prior to the study were more likely to have a negative perception of them. This study highlights the importance of providing thorough and accurate education to pediatric patients and families regarding the...
Biosimilars: A Comparative Study of Regulatory, Safety and Pharmacovigilance Monograph in the Developed and Developing Economies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35439428/
1 Biopharmaceutical and Biomarkers Discovery Laboratory, School of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan. 2 University of the Punjab, Lahore, Pakistan. Free article Free article 1 Biopharmaceutical...
Conclusion/Relevance: This article reviews the biosimilars development from the beginning (historic) to the end (development & marketing approval perspectives) and then tries to present a clear picture on areas that are still uncertain concerning the biosimilars landscape especially the biologics effect on immunogenicity, the provocative...
TNFα inhibitor biosimilars associated with alopecia areata. Case-based review - Rheumatology International
Source : https://link.springer.com/article/10.1007/s00296-022-05129-w
Alopecia areata (AA) is a common non-scaring hair loss associated with many inflammatory and autoimmune disorders. Anti-tumor necrosis factor alpha (TNFα) therapy is used to treat many chronic inflammatory disorders...
Conclusion/Relevance: These, are the first two cases of AA development during TNFα inhibitors biosimilar. Thus, physicians when dealing with patients treated with these agents, should be aware of possible immune skin reactions, among them AA. To this end, a close follow-up and monitoring is mandatory.